 |
|
New findings show Enbrel significantly reduced levels of C-reactive protein
February 04, 2008Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein (CRP), a marker of inflammation, in patients with moderate to severe plaque psoriasis following 12 weeks of treatment. Median reduction in CRP levels was 10 times greater in the ENBREL treated group compared to the placebo treated group. These results will be presented today at the American Academy of Dermatology Scientific Meeting in San Antonio, Texas.
Psoriasis is a non-contagious, chronic disease in which the immune system causes skin cells to grow at an accelerated rate. Approximately 80 percent of psoriasis patients have plaque psoriasis, which is characterized by painful and itchy, red, scaly patches.
Key findings of the analysis of moderate to severe plaque psoriasis patients without psoriatic arthritis (n=501) demonstrated:
* Patients had intermediate to high baseline CRP levels, indicating that psoriasis is a systemic inflammatory disease.
* The median reduction in CRP levels from baseline was 1.0 mg/L in psoriasis patients receiving ENBREL vs. 0.1 mg/L in those receiving placebo (P<0.001).
"The finding that patients with moderate to severe plaque psoriasis had increased inflammation, as exhibited by elevated CRP levels, reinforces that psoriasis is not only a skin disease, but in some patients may be a serious medical condition," said Bruce Strober, M.D., Ph.D., study investigator, co-director of the Psoriasis and Psoriatic Arthritis Center of New York University Medical Center. "The results from this study are encouraging because they show that ENBREL not only improved the symptoms of patients with moderate to severe psoriasis, but reduced their levels of CRP as well. However, further research is needed to better understand whether reducing CRP levels lowers the risk for developing conditions such as cardiovascular disease that may derive from increased systemic inflammation."
The analysis also evaluated the relationship between CRP levels and body mass index (BMI), an indicator of body fat, in people with psoriasis without psoriatic arthritis. Notably, obesity is common among patients with psoriasis. Findings showed:
* Heavier patients with higher BMIs tended to have higher CRP levels.
* ENBREL decreased CRP levels in overweight and obese psoriasis patients. Specifically, among patients treated with ENBREL, median CRP values decreased from high or intermediate levels to intermediate or low levels after 12 weeks of treatment in all BMI groups except normal weight psoriasis patients.
The 24-week registrational study was originally designed to test the efficacy and safety of ENBREL therapy in patients with moderate to severe plaque psoriasis, the results of which have previously been reported in The New England Journal of Medicine. The primary objective of this retrospective analysis was to evaluate the effectiveness of ENBREL in reducing levels of CRP in psoriasis patients with and without psoriatic arthritis from baseline to week 12 compared to placebo. Secondary objectives were to assess CRP values at baseline, and to assess the relationship between CRP levels and patient characteristics, such as BMI, use of statin drugs, and Psoriasis Area and Severity Index (PASI). During the double-blind portion of the analysis, patients were randomly assigned to receive either placebo or ENBREL injections (25 mg once weekly, 25 mg twice weekly or 50 mg twice weekly) for 12 weeks. During the subsequent 12 weeks, patients who initially received ENBREL continued to receive treatment with ENBREL at the same dose, while patients in the placebo group switched to ENBREL 25 mg twice weekly.
ABOUT C-REACTIVE PROTEIN
CRP is a blood protein that is a marker for a number of inflammatory conditions and is an indicator of risk for cardiovascular disease. The development of a high sensitivity CRP assay (hs-CRP) has enabled detection of low levels of CRP previously undetectable by traditional CRP evaluations. Even low levels of CRP (i.e., less than 3 mg/L), as measured by this high sensitivity test, are associated with increased cardiovascular risk; however it is not clear that CRP plays a causal role in the development of cardiovascular disease. The safety and efficacy of ENBREL have not been established for decreasing cardiovascular risk.
ABOUT ENBREL
ENBREL is a fully human soluble tumor necrosis factor (TNF) receptor. ENBREL was first approved in 1998 for moderate to severe rheumatoid arthritis and has since been used in nearly 500,000 patients worldwide across indications.
ENBREL indications in the U.S.:
* ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderate to severe rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.
* ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease modifying antirheumatic drugs.
* ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.
* ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.
* ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
What important information do I need to know about taking prescription Enbrel® (etanercept)"
ENBREL is a type of protein called a tumor necrosis factor (TNF) blocker that blocks the action of a substance your body's immune system makes called TNF. People with an immune disease, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis, have too much TNF in their bodies. ENBREL can reduce the amount of TNF in the body to normal levels, helping to treat your disease. But, in doing so, ENBREL can also lower the ability of your immune system to fight infections.
All medicines have side effects, including ENBREL. Possible side effects of ENBREL include:
* Serious infections
o Many occurred in people prone to infection, such as those with advanced or poorly controlled diabetes
o Some serious infections have been fatal
o Rare cases of tuberculosis have occurred
* What not to do
o Do not start ENBREL if you have an infection, such as an open sore or the flu, or are allergic to ENBREL or its components
* What to do
o Tell your doctor if you are prone to infection or have had hepatitis B
o Stop ENBREL if a serious infection occurs
o Contact your doctor if you have questions about ENBREL or develop an infection
o Tell your doctor if you have ever been treated for heart failure
o Serious nervous system disorders, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes
o Tell your doctor if you have ever had any of these disorders or if you develop them after starting ENBREL
* Rare reports of serious blood disorders (some fatal)
o Contact your doctor immediately if you develop symptoms, such as persistent fever, bruising, bleeding, or paleness
* In medical studies of all TNF blockers, including ENBREL, a higher rate of lymphoma (a type of cancer) was seen compared to the general population. The risk of lymphoma may be up to several-fold higher in rheumatoid arthritis and psoriasis patients
* The role of TNF blockers, including ENBREL, in the development of lymphoma is unknown
* ENBREL can cause injection site reaction
* In a medical study of patients with JRA, infection, headache, abdominal pain, vomiting, and nausea occurred more frequently than in adults
o The kinds of infections reported were generally mild and similar to those usually seen in children
o Other serious adverse reactions were reported rarely, including serious infection (2 percent) and depression/personality disorder (1 percent)
Porter Novelli
* Patients had intermediate to high baseline CRP levels, indicating that psoriasis is a systemic inflammatory disease.
* The median reduction in CRP levels from baseline was 1.0 mg/L in psoriasis patients receiving ENBREL vs. 0.1 mg/L in those receiving placebo (P<0.001).
"The finding that patients with moderate to severe plaque psoriasis had increased inflammation, as exhibited by elevated CRP levels, reinforces that psoriasis is not only a skin disease, but in some patients may be a serious medical condition," said Bruce Strober, M.D., Ph.D., study investigator, co-director of the Psoriasis and Psoriatic Arthritis Center of New York University Medical Center. "The results from this study are encouraging because they show that ENBREL not only improved the symptoms of patients with moderate to severe psoriasis, but reduced their levels of CRP as well. However, further research is needed to better understand whether reducing CRP levels lowers the risk for developing conditions such as cardiovascular disease that may derive from increased systemic inflammation."
The analysis also evaluated the relationship between CRP levels and body mass index (BMI), an indicator of body fat, in people with psoriasis without psoriatic arthritis. Notably, obesity is common among patients with psoriasis. Findings showed:
* Heavier patients with higher BMIs tended to have higher CRP levels.
* ENBREL decreased CRP levels in overweight and obese psoriasis patients. Specifically, among patients treated with ENBREL, median CRP values decreased from high or intermediate levels to intermediate or low levels after 12 weeks of treatment in all BMI groups except normal weight psoriasis patients.
The 24-week registrational study was originally designed to test the efficacy and safety of ENBREL therapy in patients with moderate to severe plaque psoriasis, the results of which have previously been reported in The New England Journal of Medicine. The primary objective of this retrospective analysis was to evaluate the effectiveness of ENBREL in reducing levels of CRP in psoriasis patients with and without psoriatic arthritis from baseline to week 12 compared to placebo. Secondary objectives were to assess CRP values at baseline, and to assess the relationship between CRP levels and patient characteristics, such as BMI, use of statin drugs, and Psoriasis Area and Severity Index (PASI). During the double-blind portion of the analysis, patients were randomly assigned to receive either placebo or ENBREL injections (25 mg once weekly, 25 mg twice weekly or 50 mg twice weekly) for 12 weeks. During the subsequent 12 weeks, patients who initially received ENBREL continued to receive treatment with ENBREL at the same dose, while patients in the placebo group switched to ENBREL 25 mg twice weekly.
ABOUT C-REACTIVE PROTEIN
CRP is a blood protein that is a marker for a number of inflammatory conditions and is an indicator of risk for cardiovascular disease. The development of a high sensitivity CRP assay (hs-CRP) has enabled detection of low levels of CRP previously undetectable by traditional CRP evaluations. Even low levels of CRP (i.e., less than 3 mg/L), as measured by this high sensitivity test, are associated with increased cardiovascular risk; however it is not clear that CRP plays a causal role in the development of cardiovascular disease. The safety and efficacy of ENBREL have not been established for decreasing cardiovascular risk.
ABOUT ENBREL
ENBREL is a fully human soluble tumor necrosis factor (TNF) receptor. ENBREL was first approved in 1998 for moderate to severe rheumatoid arthritis and has since been used in nearly 500,000 patients worldwide across indications.
ENBREL indications in the U.S.:
* ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderate to severe rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.
* ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease modifying antirheumatic drugs.
* ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.
* ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.
* ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
What important information do I need to know about taking prescription Enbrel® (etanercept)"
ENBREL is a type of protein called a tumor necrosis factor (TNF) blocker that blocks the action of a substance your body's immune system makes called TNF. People with an immune disease, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis, have too much TNF in their bodies. ENBREL can reduce the amount of TNF in the body to normal levels, helping to treat your disease. But, in doing so, ENBREL can also lower the ability of your immune system to fight infections.
All medicines have side effects, including ENBREL. Possible side effects of ENBREL include:
* Serious infections
o Many occurred in people prone to infection, such as those with advanced or poorly controlled diabetes
o Some serious infections have been fatal
o Rare cases of tuberculosis have occurred
* What not to do
o Do not start ENBREL if you have an infection, such as an open sore or the flu, or are allergic to ENBREL or its components
* What to do
o Tell your doctor if you are prone to infection or have had hepatitis B
o Stop ENBREL if a serious infection occurs
o Contact your doctor if you have questions about ENBREL or develop an infection
o Tell your doctor if you have ever been treated for heart failure
o Serious nervous system disorders, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes
o Tell your doctor if you have ever had any of these disorders or if you develop them after starting ENBREL
* Rare reports of serious blood disorders (some fatal)
o Contact your doctor immediately if you develop symptoms, such as persistent fever, bruising, bleeding, or paleness
* In medical studies of all TNF blockers, including ENBREL, a higher rate of lymphoma (a type of cancer) was seen compared to the general population. The risk of lymphoma may be up to several-fold higher in rheumatoid arthritis and psoriasis patients
* The role of TNF blockers, including ENBREL, in the development of lymphoma is unknown
* ENBREL can cause injection site reaction
* In a medical study of patients with JRA, infection, headache, abdominal pain, vomiting, and nausea occurred more frequently than in adults
o The kinds of infections reported were generally mild and similar to those usually seen in children
o Other serious adverse reactions were reported rarely, including serious infection (2 percent) and depression/personality disorder (1 percent)
Porter Novelli
Psoriasis News and Current Psoriasis Events RSSGeisinger study: PTSD causes early death from heart disease
Vietnam veterans who experienced posttraumatic stress disorder (PTSD) were twice as likely to die from heart disease as veterans without PTSD, a new Geisinger study finds.
Complexity of Crohn's disease revealed as 'gene' count tops 30
New research has trebled the number of genetic regions known to be implicated in Crohn's disease, a form of inflammatory bowel disease, to over thirty.
Scientist study bacterial communities inside us to better understand health and disease
The number of bacteria living within the body of the average healthy adult human are estimated to outnumber human cells 10 to 1. Changes in these microbial communities may be responsible for digestive disorders, skin diseases, gum disease and even obesity.
Inflammation, depression and antidepressant response: Common mechanisms
Major depressive disorder is a common and complex condition that impacts about 15% of the population of the United States, yet very little is known about the mechanisms behind the psychiatric disorder.
Watery pools in bone marrow key to psoriatic arthritic damage
Researchers have learned more about how a leading drug prevents certain types of arthritis from eating away at bone, according to a study published in the March edition of the Annals of the Rheumatic Diseases.
Popular alternative therapy for psoriasis performs no better than placebo
Anecdotal evidence touting the healing power of the Indian spice turmeric for psoriasis received a setback in a prospective study published this month by a leading dermatology journal stating that the low response rate of patients who ingested the active ingredient of the exotic spice was probably a result of the placebo effect.
Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis
One-year data from a second double-blind, placebo-controlled Phase 3 study showed therapy with ustekinumab given every 12 weeks provided sustained, clinically meaningful improvement in the treatment of moderate to severe plaque psoriasis through one year.
Severe psoriasis associated with increased risk of death
Patients with severe psoriasis appear to have an increased risk of death compared with patients without the skin condition, according to a report in the December issue of Archives of Dermatology, one of the JAMA/Archives journals.
Phase 3 data show golimumab improved psoriatic arthritis symptoms
Patients with active psoriatic arthritis receiving monthly subcutaneous (SC) injections of golimumab (CNTO 148) experienced significant and sustained improvements in the joint and skin manifestations of the disease.
Scientists complete genome sequence of fungus responsible for dandruff, skin disorders
Scientists from P&G Beauty announced that they successfully sequenced the complete genome for Malassezia globosa (M. globosa), a naturally occurring fungus responsible for the onset of dandruff and other skin conditions in humans.
More Psoriasis News Articles
 | Healing Psoriasis: The Natural Alternative by John Pagano A leading researcher shares natural remedies for psoriasis According to the National Psoriasis Foundation, at least seven million people in the U.S. and more than 100 million worldwide suffer from this chronic skin disease. This book outlines Dr. Pagano's natural, drug-free treatment regimen that can alleviate, control, and even heal psoriasis without steroid creams, tar baths, injections, or... |
 | Your Healing Diet: A Quick Guide to Reversing Psoriasis and Chronic Diseases with Healing Foods by Deirdre RD Earls 'Your Healing Diet: A Quick Guide to Reversing Psoriasis and Chronic Diseases with Healing Foods' is a handbook written by Deirdre Earls, RD, LD, to make it faster and easier to eat in a way that enables the body to heal itself. A short guidebook which was designed to be very user-friendly, it also explains how food can create and reverse disease. In essense, the book distills common threads... |
 | The Psoriasis Cure: A Drug-Free Guide to Stopping & Reversing the Symptoms of Psoriasis by Lisa LeVan This book offers hope for those who suffer from this debilitating systemic disease. Beyond causing scaly red patches on the skin, psoriasis can result in aching joints, listlessness, and arthritis. Featuring a nutritional approach to treatment, this book teaches the patient to eliminate allergic reactions and to add specific supplements to the... |
 | Psoriasis, Healing from the Inside Out by Heather J. Ferris An important book for people with psoriasis and other conditions, who feel controlled by their diseases. This book addresses issues of the body, mind and spirit. It also provides practical techniques and opportunities to reflect on individual situations and to make the necessary... |
 | Understanding Skin Problems: Acne, Eczema, Psoriasis and Related Conditions by Linda Papadopoulos, Carl Walker As suffers will know, any dermatological condition can have a devastating effect leading to feelings of isolation and depression. Filling the gap between medical advice and lay knowledge, Understanding Skin Problems provides crucial information to help you understand the various aspects of your condition - psychological and social as well as medical - so that you can improve the quality... |
 | Psoriasis: Everything You Need to Know (Your Personal Health) by Richard G.B. Langley Helpful advice for relief of a chronic condition that affects millions. Psoriasis is a chronic inflammatory, non-contagious skin disease. Characterized by itchy, thick and raised red areas of skin covered with silvery-white scales, psoriasis affects 1 in 50 adults. This affliction makes it one of the world's most common skin disorders. Appearing at any age, it can affect relationships, the... |
 | Eczema and Psoriasis: How Your Diet Can Help (Nutritional Health Guide) by Stephen Terrass Explains the facts about eczema and psoriasis, which foods to eat, which foods to avoid, and the benefits of vitamins, minerals, herbal, and other nutritional... |
 | Psoriasis: The Real Way Out: A Self-Education Guide to Complete Natural Healing by Jerry G. Scott R.N.C. This is a book for the determined, not for the quick fix crowd. A clear understanding of the underlying causes of psoriasis is presented, one that flies in the face of current drug-oriented treatments, nevertheless one that recognizes the causes and alleviation of psoriasis that have been known for decades. Leading edge strategies are also revealed, and resources are listed. The book is blunt,... |
| Evaluating the role of phototherapy for moderate to severe Psoriasis: Skin cancer and phototherapy; Defining the real risk. (Clinical Update).: An article from: Skin & Allergy News This digital document is an article from Skin & Allergy News, published by International Medical News Group on April 1, 2002. The length of the article is 425 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation... | |
 | Handbook of Psoriasis by Charles Camisa The new second edition of the Handbook of Psoriasis remains an easy-to-read but detailed text on a common skin disease which affects 20f the world's population. The text is designed as a reference for both the specialist and the primary care physician and can be read cover-to-cover in a week. Each chapter stands alone as a reference to a specific topic but is clearly cross-referenced to offer a... |
| © 2008 BrightSurf.com |